vs
PHIBRO ANIMAL HEALTH CORP（PAHC）与Reddit, Inc.（RDDT）财务数据对比。点击上方公司名可切换其他公司
Reddit, Inc.的季度营收约是PHIBRO ANIMAL HEALTH CORP的1.9倍（$725.6M vs $373.9M），Reddit, Inc.净利率更高（34.7% vs 7.3%，领先27.3%），Reddit, Inc.同比增速更快（69.7% vs 20.9%），Reddit, Inc.自由现金流更多（$263.6M vs $8.3M），过去两年Reddit, Inc.的营收复合增速更高（72.8% vs 19.2%）
菲宝罗动物保健公司是一家美国动物健康与矿物质营养企业，主营产品涵盖抗菌药、抗球虫药、驱虫药，以及畜禽营养补充剂、疫苗等。公司下设矿物质营养、功能材料、动物健康三大业务板块，收入主要来源于上述板块，业务遍及美国、拉美、加拿大、欧洲、中东、非洲及亚太地区。
Reddit是美国知名的社交新闻聚合与论坛类社交媒体平台，注册用户可发布链接、文字帖、图片、视频等各类内容，其他用户可对内容进行点赞或点踩，内容按主题归类到用户创建的子板块中，获赞更高的内容会排在板块前列，热度足够的内容还将展示在全站首页。
PAHC vs RDDT — 直观对比
营收规模更大
RDDT
是对方的1.9倍
$373.9M
营收增速更快
RDDT
高出48.7%
20.9%
净利率更高
RDDT
高出27.3%
7.3%
自由现金流更多
RDDT
多$255.4M
$8.3M
两年增速更快
RDDT
近两年复合增速
19.2%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $373.9M | $725.6M |
| 净利润 | $27.5M | $251.6M |
| 毛利率 | 35.5% | 91.9% |
| 营业利润率 | 13.5% | 31.9% |
| 净利率 | 7.3% | 34.7% |
| 营收同比 | 20.9% | 69.7% |
| 净利润同比 | 762.1% | 254.2% |
| 每股收益（稀释后） | $0.67 | $1.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PAHCRDDT
| Q4 25 | $373.9M | $725.6M | ||
| Q3 25 | $363.9M | $584.9M | ||
| Q2 25 | $378.7M | $499.6M | ||
| Q1 25 | $347.8M | $392.4M | ||
| Q4 24 | $309.3M | $427.7M | ||
| Q3 24 | $260.4M | $348.4M | ||
| Q2 24 | $273.2M | $281.2M | ||
| Q1 24 | $263.2M | $243.0M |
净利润PAHCRDDT
| Q4 25 | $27.5M | $251.6M | ||
| Q3 25 | $26.5M | $162.7M | ||
| Q2 25 | $17.2M | $89.3M | ||
| Q1 25 | $20.9M | $26.2M | ||
| Q4 24 | $3.2M | $71.0M | ||
| Q3 24 | $7.0M | $29.9M | ||
| Q2 24 | $752.0K | $-10.1M | ||
| Q1 24 | $8.4M | $-575.1M |
毛利率PAHCRDDT
| Q4 25 | 35.5% | 91.9% | ||
| Q3 25 | 32.9% | 91.0% | ||
| Q2 25 | 29.0% | 90.8% | ||
| Q1 25 | 30.1% | 90.5% | ||
| Q4 24 | 32.9% | 92.6% | ||
| Q3 24 | 32.1% | 90.1% | ||
| Q2 24 | 31.9% | 89.5% | ||
| Q1 24 | 30.2% | 88.6% |
营业利润率PAHCRDDT
| Q4 25 | 13.5% | 31.9% | ||
| Q3 25 | 14.1% | 23.7% | ||
| Q2 25 | 8.9% | 13.6% | ||
| Q1 25 | 9.6% | 1.0% | ||
| Q4 24 | 8.3% | 12.4% | ||
| Q3 24 | 6.8% | 2.0% | ||
| Q2 24 | 6.7% | -11.0% | ||
| Q1 24 | 7.6% | -242.5% |
净利率PAHCRDDT
| Q4 25 | 7.3% | 34.7% | ||
| Q3 25 | 7.3% | 27.8% | ||
| Q2 25 | 4.5% | 17.9% | ||
| Q1 25 | 6.0% | 6.7% | ||
| Q4 24 | 1.0% | 16.6% | ||
| Q3 24 | 2.7% | 8.6% | ||
| Q2 24 | 0.3% | -3.6% | ||
| Q1 24 | 3.2% | -236.7% |
每股收益（稀释后）PAHCRDDT
| Q4 25 | $0.67 | $1.24 | ||
| Q3 25 | $0.65 | $0.80 | ||
| Q2 25 | $0.43 | $0.45 | ||
| Q1 25 | $0.51 | $0.13 | ||
| Q4 24 | $0.08 | $4.76 | ||
| Q3 24 | $0.17 | $0.16 | ||
| Q2 24 | $0.02 | $-0.06 | ||
| Q1 24 | $0.21 | $-8.19 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $74.5M | $953.6M |
| 总债务越低越好 | $624.2M | — |
| 股东权益账面价值 | $332.4M | $2.9B |
| 总资产 | $1.4B | $3.2B |
| 负债/权益比越低杠杆越低 | 1.88× | — |
8季度趋势，按日历期对齐
现金及短期投资PAHCRDDT
| Q4 25 | $74.5M | $953.6M | ||
| Q3 25 | $85.3M | $911.7M | ||
| Q2 25 | $77.0M | $734.1M | ||
| Q1 25 | $70.4M | $635.7M | ||
| Q4 24 | $67.1M | $562.1M | ||
| Q3 24 | $89.8M | $515.9M | ||
| Q2 24 | $114.6M | $468.0M | ||
| Q1 24 | $98.7M | $968.5M |
总债务PAHCRDDT
| Q4 25 | $624.2M | — | ||
| Q3 25 | $628.0M | — | ||
| Q2 25 | $631.7M | — | ||
| Q1 25 | $635.4M | — | ||
| Q4 24 | $639.1M | — | ||
| Q3 24 | $295.2M | — | ||
| Q2 24 | $312.1M | — | ||
| Q1 24 | — | — |
股东权益PAHCRDDT
| Q4 25 | $332.4M | $2.9B | ||
| Q3 25 | $311.7M | $2.6B | ||
| Q2 25 | $285.7M | $2.4B | ||
| Q1 25 | $266.0M | $2.2B | ||
| Q4 24 | $246.8M | $2.1B | ||
| Q3 24 | $258.5M | $2.0B | ||
| Q2 24 | $256.6M | $1.9B | ||
| Q1 24 | $270.1M | $1.8B |
总资产PAHCRDDT
| Q4 25 | $1.4B | $3.2B | ||
| Q3 25 | $1.4B | $2.9B | ||
| Q2 25 | $1.4B | $2.6B | ||
| Q1 25 | $1.3B | $2.4B | ||
| Q4 24 | $1.3B | $2.3B | ||
| Q3 24 | $966.3M | $2.2B | ||
| Q2 24 | $982.2M | $2.1B | ||
| Q1 24 | $979.0M | $2.0B |
负债/权益比PAHCRDDT
| Q4 25 | 1.88× | — | ||
| Q3 25 | 2.01× | — | ||
| Q2 25 | 2.21× | — | ||
| Q1 25 | 2.39× | — | ||
| Q4 24 | 2.59× | — | ||
| Q3 24 | 1.14× | — | ||
| Q2 24 | 1.22× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.4M | $266.8M |
| 自由现金流经营现金流 - 资本支出 | $8.3M | $263.6M |
| 自由现金流率自由现金流/营收 | 2.2% | 36.3% |
| 资本支出强度资本支出/营收 | 3.0% | 0.4% |
| 现金转化率经营现金流/净利润 | 0.70× | 1.06× |
| 过去12个月自由现金流最近4个季度 | $47.3M | $684.2M |
8季度趋势，按日历期对齐
经营现金流PAHCRDDT
| Q4 25 | $19.4M | $266.8M | ||
| Q3 25 | $9.3M | $185.2M | ||
| Q2 25 | $21.3M | $111.3M | ||
| Q1 25 | $43.2M | $127.6M | ||
| Q4 24 | $3.1M | $90.0M | ||
| Q3 24 | $12.6M | $71.6M | ||
| Q2 24 | $28.4M | $28.4M | ||
| Q1 24 | $11.4M | $32.1M |
自由现金流PAHCRDDT
| Q4 25 | $8.3M | $263.6M | ||
| Q3 25 | $-4.5M | $183.1M | ||
| Q2 25 | $8.1M | $110.8M | ||
| Q1 25 | $35.4M | $126.6M | ||
| Q4 24 | $-4.7M | $89.2M | ||
| Q3 24 | $3.0M | $70.3M | ||
| Q2 24 | $15.4M | $27.2M | ||
| Q1 24 | $1.7M | $29.2M |
自由现金流率PAHCRDDT
| Q4 25 | 2.2% | 36.3% | ||
| Q3 25 | -1.2% | 31.3% | ||
| Q2 25 | 2.1% | 22.2% | ||
| Q1 25 | 10.2% | 32.3% | ||
| Q4 24 | -1.5% | 20.8% | ||
| Q3 24 | 1.2% | 20.2% | ||
| Q2 24 | 5.6% | 9.7% | ||
| Q1 24 | 0.6% | 12.0% |
资本支出强度PAHCRDDT
| Q4 25 | 3.0% | 0.4% | ||
| Q3 25 | 3.8% | 0.4% | ||
| Q2 25 | 3.5% | 0.1% | ||
| Q1 25 | 2.2% | 0.2% | ||
| Q4 24 | 2.5% | 0.2% | ||
| Q3 24 | 3.7% | 0.4% | ||
| Q2 24 | 4.8% | 0.4% | ||
| Q1 24 | 3.7% | 1.2% |
现金转化率PAHCRDDT
| Q4 25 | 0.70× | 1.06× | ||
| Q3 25 | 0.35× | 1.14× | ||
| Q2 25 | 1.24× | 1.25× | ||
| Q1 25 | 2.07× | 4.88× | ||
| Q4 24 | 0.97× | 1.27× | ||
| Q3 24 | 1.81× | 2.40× | ||
| Q2 24 | 37.80× | — | ||
| Q1 24 | 1.36× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PAHC
| Medicated Feed Additives And Others | $202.1M | 54% |
| Mineral Nutrition | $68.9M | 18% |
| Nutritional Specialties | $50.2M | 13% |
| Vaccines | $37.6M | 10% |
| Performance Products | $15.0M | 4% |
RDDT
| Advertising | $689.7M | 95% |
| Other Revenue | $35.9M | 5% |
